Last €0.18 EUR
Change Today +0.008 / 4.73%
Volume 0.0
PBN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
OTC US
Stuttgart
As of 2:13 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PBN) Snapshot

Open
€0.18
Previous Close
€0.17
Day High
€0.18
Day Low
€0.18
52 Week High
01/31/14 - €0.93
52 Week Low
05/8/14 - €0.09
Market Cap
86.5M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
488.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRANA BIOTECHNOLOGY LTD (PBN)

Related News

No related news articles were found.

prana biotechnology ltd (PBN) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PBN) Details

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer and age-related macular degeneration. The company’s product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer’s disease, as well as in Phase IIa clinical trials to treat Huntington’s disease. Its preclinical products comprise PBT434 for the treatment of Alzheimer’s disease; and PBT519 to treat brain cancer. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

9 Employees
Last Reported Date: 08/30/13
Founded in 1997

prana biotechnology ltd (PBN) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$426.5K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$77.3K
Chief Operating Officer
Total Annual Compensation: A$318.0K
Compensation as of Fiscal Year 2013.

prana biotechnology ltd (PBN) Key Developments

Prana Biotechnology Limited Announces Joining of Ira Shoulson to the Board of Directors as Non Executive Director

Prana Biotechnology Limited announced joining of Ira Shoulson to it's board of directors as a non-executive director effective immediately. Professor Shoulson is one of the experts in neurodegenerative diseases and movement disorders, and the founder of international academic consortia the Huntington Study Group and Parkinson Study Group. and Medicine (PRSM). He is also principal investigator of the Georgetown University Center of Excellence in Regulatory Science and Innovation (CERSI). Professor Shoulson has served as a consultant to, and member of, several FDA advisory committees over the past three decades, and has been involved in eight successful new drug applications to the FDA. Prior to taking up his position with Prana, Professor Shoulson concluded his elected term as Chair and President of the Huntington Study Group.

Prana Biotechnology Limited - Special Call

To discuss the results of the 12-month Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology Limited Announces Preliminary Results of Phase 2 Imagine Trial of PBT2 in Alzheimer's Disease

Prana Biotechnology Limited has released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease, based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value Ratio. Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well. No improvement was observed on the secondary endpoints of brain metabolic activity, cognition and function; however there was a trend towards preserving hippocampal brain volume in the PBT2 group. Specifically, there was less atrophy in those patients treated with PBT2 relative to placebo, 2.6% and 4.0%, respectively. This is consistent with published measures of atrophy in AD patients versus healthy controls of 4.7% and 1.4%, respectively. The company is tracking measures of brain volume and cognition in the current 12 month extension study that will be completed at the end of the year. Further analysis of the results is ongoing. Importantly, PBT2 was shown to be safe and very well tolerated over the 52 weeks. The adverse event profile was equivalent between placebo and treated groups. Forty of the 42 enrolled participants completed the 52 week treatment period. Prana is proceeding with its plans toward a confirmatory study for Huntington disease. Based on Prana's previous discussion with the US Food and Drug Administration, the data on safety and tolerability of PBT2 in Alzheimer's disease will support the future clinical development and, ultimately, a New Drug Application in Huntington disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBN:GR €0.18 EUR +0.008

PBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBN.
View Industry Companies
 

Industry Analysis

PBN

Industry Average

Valuation PBN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.2x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.